ArticleCell reports2024
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy.
Abstract readComparative Study
In one paragraph
Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Context-dependent TREM2 signalling in myeloid cells: Molecular mechanisms and immunotherapeutic divergence in neurodegeneration and cancer.Clinical and translational medicine · 2026Review
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- The DNA damage response and cancer immunotherapy.Nature reviews. Cancer · 2026Review
- XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer.Nature communications · 2026Article
- Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Spatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- T-cell exhaustion in tumor immunology: mechanisms, heterogeneity, and therapeutic strategies.Frontiers in immunology · 2026Review
- Revisiting TREM2: from multi-omics signaling networks to clinical translation.Frontiers in immunology · 2026Review
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
- Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade.bioRxiv : the preprint server for biology · 2025Article
- Computational neoantigen prediction for cancer immunotherapy.Genes and immunity · 2025Review
- TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects.NPJ precision oncology · 2025Review
- Targeting the CD47-TSP1 Axis in Abdominal Aortic Aneurysm: A Novel Immunotherapeutic Approach.International journal of molecular sciences · 2025Review
- Bhlhe40 Coordinates T Cell Programs with Distinct CD4 and CD8 T Cell Requirements for Anti-PD-1 Versus Anti-CTLA-4.bioRxiv : the preprint server for biology · 2025Article
- Targeting neoantigens conserved across organs and species overcomes tumor immune escape.bioRxiv : the preprint server for biology · 2025Article
- Delivery and adjuvant: liposomes for SARS-CoV-2 vaccines.Biotechnologia · 2025Review
- Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.Frontiers in immunology · 2025Review
Corrections and comments
- Update of
Authors and funding
17 authors.
Sunita KeshariDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alexander S ShavkunovDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qi MiaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Akata SahaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tomoyuki MinowaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Martina MolgoraDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Charmelle D WilliamsDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mehdi ChaibDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anna M HighsmithDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Josué E PinedaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sayan AlekseevDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Program of Biology, The University of Texas at San Antonio, San Antonio, TX, USA.
Elise AlspachDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA.
Kenneth H HuDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Kristen E PaukenDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ken ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matthew M GubinDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mgubin@mdanderson.org.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MThe University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3MBhlhe40 Regulation of T Cell Function During Cancer ImmunotherapyR01CA282027 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Matthew M. Gubin · 2024 to 2026
$3.0MTargeting TREM2 to boost anti-cancer therapyR01CA262684 · NCI · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2021 to 2025
$2.1MInformatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing DataU01CA247760 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, KEN · 2020 to 2022
$1.2MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA262684NCI NIH HHS R01 CA282027NCI NIH HHS U01 CA247760
Abstract
The goal of therapeutic cancer vaccines and immune checkpoint therapy (ICT) is to promote T cells with anti-tumor capabilities. Here, we compared mutant neoantigen (neoAg) peptide-based vaccines with ICT in preclinical models. NeoAg vaccines induce the most robust expansion of proliferating and stem-like PD-1
Indexed as
Antigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsMacrophagesReceptors, ImmunologicAnimalsCell Line, TumorCTLA-4 AntigenFemaleHumansImmunotherapyMannose ReceptorMembrane GlycoproteinsMiceMice, Inbred C57BLAntigens, NeoplasmCancer VaccinesCTLA-4 AntigenImmune Checkpoint InhibitorsMannose ReceptorMembrane GlycoproteinsProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTrem2 protein, mouseanti-CTLA-4/anti-PD-1cancer immunotherapyCD4 T cellscombination immunotherapyCP: CancerCP: Immunologyimmune checkpoint therapyintratumoral macrophagesneoantigen cancer vaccinesneoantigen-specific CD8 T cellsTREM2tumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.